July/August

A specialty pharmacy’s specific expertise and experience in supporting patients with cancer is among its most essential attributes.

States are getting inventive in their approaches to meeting the health care needs of their citizens, especially when it comes to curative treatments for conditions that have a high prevalence rate.

As the deadline for full implementation approaches, hospitals must create an action plan and timeline for completion.

Cannabidiol (CBD) has certainly drawn significant attention over the past few months.

A strong partnership can support the successful commercialization of a product, position the therapy to meet a manufacturer’s business goals, and provide patients with an option to improve their health and quality of life.

On July 20, 2018, the FDA approved ivosidenib (Tibsovo) as a treatment option for adult patients with relapsed/refractory acute myeloid leukemia, specifically with a mutation in the IDH1 gene.

Within this evolving new world of health care are the questions surrounding the future of smaller independent pharmacies.

Independent specialty pharmacy must see health care cost through a different lens.

It is important to promote the ongoing development of best practices for integrated specialty pharmacies in academic health systems.

In a Specialty Pharmacy Times® Insights video series, experts Atul A. Deodhar, MD, and Hillary Norton, MD, discussed clinical best practices surrounding the diagnosis, management, and treatment of AxSpA, including an overview of available therapies.

Keycentrix, a software and technology company specializing in pharmacy and health care, develops and implements technology solutions with pharmacists in mind.

The clinical assessment has long been a cornerstone of patient-centric specialty pharmacy care.

With ongoing growth across the board, plan sponsors are continuously searching for ways to minimize the impact on their bottom line.